Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

Cell Reports(2021)10.1016/j.celrep.2021.109452Source: DataRank Database

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice is a research paper published in Cell Reports (2021). On theSindex it has a DataRank of 0. It has been cited 136 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access136 citations

Download PDF

Cite:

Linked data & code

cellosaurus nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 7.25)OA: goldTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

Swathi Shrihari ORCID,Matthew J. Gorman,Baoling Ying,Dansu Yuan ORCID,Saravanan Raju ORCID

Live enrichment

PubMed:34289385 PMC:PMC8270739 OpenAlex:https://openalex.org/W3179359240

NIAID NIH HHS

Grant: R01 AI157155

NIBIB NIH HHS

Grant: R01 EB026468

NIAID NIH HHS

Grant: HHSN272201400018C

NIAID NIH HHS

Grant: 75N93021C00017

NIGMS NIH HHS

Grant: T32 GM007200

NIAID NIH HHS

Grant: 75N93019C00062

National Institutes of Health

Grant: 1R01EB026468-01A1

Novel Vector Platform for Gene Therapy

National Institutes of Health

Grant: 5R01AI157155-02

Human antibody-based countermeasures against the Coronavirus SARS-CoV-2

Bill and Melinda Gates Foundation

National Institute of Health and Medical Research

FWCI

7.25

Citation Percentile

1.0%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.celrep.2021.109452

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270739

publisherhttps://doi.org/10.1016/j.celrep.2021.109452

publisherhttps://api.elsevier.com/content/article/PII:S221112472100869X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S221112472100869X?httpAccept=text/plain

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testingBiologyMedicine0301 basic medicine03 medical and health sciences

MeSH Terms

SARS-CoV-2Administration, IntranasalAnimalsAntibodies, ViralVaccinationViral VaccinesMiceAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

Nasal administrationAntibodyVirologyImmunizationNeutralizationVaccinationImmunologyNeutralizing antibodyMedicineAttenuated vaccineBiologyVirusImmune systemGeneMiceVaccinePathogenesisMucosal immunityDurabilityCovid-19Sars-cov-2Variants Of ConcernQH301-705.5Antibodies, ViralAntibodiesArticleAnimalsViralBiology (General)NeutralizingAdministration, IntranasalViral VaccinesAntibodies, NeutralizingSpike GlycoproteinCoronavirusIntranasalAdministrationSpike Glycoprotein, Coronavirus

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

FAIR Checklist

Authors (19)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)